MedPath

Clinical Trial News

Lenvatinib and Pembrolizumab Combination Shows Promise in Advanced Thymic Epithelial Tumors

  • The combination of lenvatinib and pembrolizumab demonstrated a promising 5-month progression-free survival (PFS) rate of nearly 90% in patients with platinum-refractory advanced thymic epithelial tumors.
  • Median PFS reached 14.9 months, with a 12-month PFS rate of 56%, indicating a potential new standard treatment for advanced B3-thymoma and thymic carcinoma.
  • The combination showed an objective response rate of 23.3% and manageable safety profile, though close monitoring for adverse events is crucial for optimal patient management.

Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

NCT04710628Active, Not RecruitingPhase 2
MedSIR
Posted 9/21/2021

Comprehensive Digital System Reduces Symptom Burden in Cancer Patients Undergoing Chemotherapy

  • A randomized clinical trial evaluated the efficacy of a multicomponent digital intervention, Symptom Care at Home (SCH), in reducing symptom burden among cancer patients undergoing chemotherapy.
  • The complete SCH intervention, which includes automated self-management coaching and nurse practitioner (NP) follow-up with decision support, significantly reduced symptom burden compared to individual components alone.
  • NP follow-up was superior to self-management coaching, but there was no significant difference between activity tracker groups or between the two NP groups.
  • The study suggests that a comprehensive, multicomponent digital approach to cancer symptom management offers optimal symptom burden reduction and improved symptom control during chemotherapy.

SymptomCare@Home: Deconstructing an Effective Symptom Management Intervention

NCT02779725CompletedNot Applicable
University of Utah
Posted 8/7/2017

Fixed-Duration Venetoclax Regimens Offer CLL Patients a Balanced Approach

  • Fixed-duration treatments in CLL offer a defined treatment period, contrasting with continuous therapies that require ongoing administration until disease progression or unacceptable toxicity.
  • Venetoclax-based regimens, such as venetoclax plus obinutuzumab for 12 cycles in the frontline setting, provide a time-limited treatment option.
  • In the relapsed/refractory setting, venetoclax combined with rituximab is approved for 24 cycles, offering another fixed-duration approach for CLL management.

Real-World Study Uncovers Factors Influencing Long-Term Weight Loss with GLP-1 RAs

• A Cleveland Clinic study identifies that the active agent, dosage, treatment indication, and persistence significantly impact long-term weight loss with GLP-1 RAs. • Semaglutide demonstrates a greater average weight reduction compared to liraglutide, with higher doses leading to more significant weight loss. • Patients treated for obesity showed better weight loss outcomes than those treated for type 2 diabetes, especially with consistent medication use. • Achieving at least 10% body weight reduction was more likely with semaglutide, higher doses, obesity treatment, and higher initial BMI.

VO659 Shows Promise in Reducing Mutant Huntingtin Protein in Huntington's Disease Patients

  • Interim Phase 1/2 data shows VO659, an antisense oligonucleotide, reduces mutant huntingtin protein (mHTT) in Huntington's disease patients.
  • Patients treated with 40mg of VO659 experienced a 28% mean reduction in mHTT in cerebrospinal fluid by day 85.
  • The treatment was generally safe and well-tolerated, with no significant changes in neurofilament light protein levels.
  • VO659's long half-life suggests potential for infrequent dosing, possibly once or twice per year, offering convenience.

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

NCT05822908RecruitingPhase 1
Vico Therapeutics B. V.
Posted 2/14/2023

Semaglutide Outperforms Liraglutide for Weight Loss in Real-World Study

• Semaglutide (Ozempic, Wegovy) leads to ≥10% weight loss in 61% of obesity patients and 23% of diabetes patients, significantly higher than liraglutide (Saxenda). • Liraglutide achieved similar weight loss in only 29% of obesity patients and 12% of type 2 diabetes patients over one year. • The study highlights that higher doses of semaglutide and adherence to the drug schedule are associated with greater weight loss. • Findings emphasize the importance of medication persistence and patient-specific factors in achieving clinically significant weight reduction with GLP-1 receptor agonists.

AstraZeneca's Truqap (capivasertib) Launched in Korea as First AKT Inhibitor for Breast Cancer

  • AstraZeneca Korea has launched Truqap (capivasertib), the first AKT inhibitor approved in Korea, for HR-positive/HER2-negative breast cancer patients with specific mutations.
  • The approval was based on the CAPItello-291 trial, which showed a significant improvement in median progression-free survival when combined with fulvestrant.
  • Truqap targets PIK3CA, AKT1, or PTEN mutations, present in approximately 50% of HR-positive/HER2-negative breast cancer patients, addressing a critical need for effective second-line therapies.
  • Concerns remain regarding the financial burden on patients due to the high cost of next-generation sequencing (NGS) required to identify eligible patients.

Inhaled Colistimethate Shows Promise for Bronchiectasis, Despite COVID-19 Impact

  • In the PROMIS-I trial, inhaled colistimethate sodium significantly reduced the mean annual exacerbation rate in bronchiectasis patients with Pseudomonas aeruginosa infections.
  • The PROMIS-II trial, impacted by the COVID-19 pandemic, did not show a significant reduction in exacerbation rates with the same treatment.
  • A meta-analysis of PROMIS-I, pre-pandemic PROMIS-II data, and an earlier phase II study supported the efficacy of colistimethate sodium in reducing exacerbation rates.
  • Inhaled colistimethate sodium demonstrated a safety profile similar to placebo, with low rates of bronchospasm and manageable adverse events.

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.

NCT03460704TerminatedPhase 3
Zambon SpA
Posted 1/29/2018

Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)

NCT03093974CompletedPhase 3
Zambon SpA
Posted 6/6/2017

Endo's Collagenase Clostridium Histolyticum Shows Promise in Phase 2 Plantar Fibromatosis Study

  • Endo presented Phase 2 clinical trial data of collagenase clostridium histolyticum (CCH) for plantar fibromatosis at the AOFAS annual meeting.
  • The study demonstrated a trend toward pain reduction with CCH treatment compared to placebo, as measured by the Foot Function Index.
  • CCH showed nominally significant improvements in investigator assessments of the condition, nodule hardness, and nodule consistency.
  • The safety profile of CCH in the study was consistent with previous findings, with mostly mild to moderate local adverse events reported.

Librexia Program Aims for Inclusive Cardiovascular Clinical Trials

  • The Librexia program is a Phase 3 clinical trial focusing on novel treatments for blood clotting diseases, including acute coronary syndrome and atrial fibrillation.
  • The trial actively recruits women and people of color to ensure inclusive and equitable results relevant to all patient populations.
  • Cardiovascular diseases and stroke remain leading causes of death, with disparities in care partly due to underrepresentation in clinical trials.
  • Diverse representation in clinical trials is crucial for understanding medication benefits across all population segments, according to Dr. Roxana Mehran.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.